DASH vs DMAC
DoorDash, Inc. Class A Common Stock (DASH) versus DiaMedica Therapeutics Inc (DMAC) — a side-by-side from cached financials, not a winner call.
DoorDash, Inc. Class A Common Stock (DASH) is a internet retail company listed on US.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Latest reported DASH revenue for 2025-12-31 was $13.72B. Net income was $935.0M. Revenue was up 27.9% from 2024-12-31 to 2025-12-31. DASH currently screens at market cap $69.41B and trailing P/E 75.9.
DMAC does not have a complete income-statement cache yet.
DASH currently screens at market cap $69.41B and trailing P/E 75.9. DMAC currently screens at market cap $157.4M.
Not investment advice. Open the DASH and DMAC stock pages for the full models.
Not investment advice.